It is interesting to note that the use of dual anti-EGFR and HER3 antibody MEHD7945A has been shown to be more effective in inhibiting the proliferation of HNSCC cells in vitro and inhibiting the growth of xenografts tumors in vivo than cetuximab alone [18], suggesting that pan-EGFR inhibition could effectively inhibit or radiosensitize tumors and prevent recurrent tumors. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.